RBC Capital Maintains Outperform on 4D Molecular Therapeutics, Raises Price Target to $40
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Luca Issi has maintained an Outperform rating on 4D Molecular Therapeutics (NASDAQ:FDMT) and increased the price target from $35 to $40.
April 15, 2024 | 5:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital has reaffirmed its Outperform rating on 4D Molecular Therapeutics and raised the price target from $35 to $40.
The upgrade in price target by a reputable analyst like Luca Issi at RBC Capital suggests a strong confidence in the future performance of 4D Molecular Therapeutics. This is likely to be viewed positively by the market, potentially leading to an increase in the stock price in the short term as investors adjust their expectations based on this new analyst target.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100